Plasma Phosphorylated Tau 217 and Incident MCI and Dementia in Older Women This cohort study examines associations of baseline plasma phosphorylated tau 217 with incident mild cognitive impairment (MCI) or dementia and whether associations vary by age, race, APOE ε4 carrier ...

En mujeres mayores sin deterioro cognitivo el p-tau217 se asocia con deterioro cognitivo leve o demencia hasta 25a más tarde, considerando la edad, raza, portador de APOE epsilon 4 y uso de terapia hormonal #ptau217 #dementia #women jamanetwork.com/journals/jam...

Two bar graphs, titled 'Figure 3. Economic Impact of 3 Phosphorylated Tau 217 Testing Strategies Across Biological Subgroups.' Graph A shows 'UGOT cohort', and Graph B shows 'Roche cohort'. Both compare 'Total cost, $1000' across subgroups.

Biologically informed plasma #pTau217 thresholds improved diagnostic accuracy for amyloid PET positivity in patients with #CKD and #anemia vs a standard single cutoff, supporting cost-efficient biomarker implementation in #AlzheimerDisease screening. ja.ma/4rx8Vsu

ALZpath’s pTau217 Antibody Sets New Standard for Blood-Based Alzheimer's Diagnostics ALZpath's pTau217 antibody has been validated as a leading blood-based biomarker for Alzheimer's disease, demonstrating exceptional diagnostic accuracy at the AD/PD™ 2026 Conference.

ALZpath’s pTau217 Antibody Sets New Standard for Blood-Based Alzheimer's Diagnostics #USA #Alzheimer's #Carlsbad #ALZpath #pTau217

Nieuwe bloedtest voorspelt begin Alzheimer-symptomen In het kort Er is een baanbrekende bloedtest ontwikkeld die veelbelovend is voor het voorspellen van het begin van symptomen van de ziekte van Alzheimer. Deze simpele test kijkt naar de p-tau217-waarden, een eiwit dat in plasma zit, waardoor onderzoekers kunnen inschatten wanneer iemand cognitieve achteruitgang kan krijgen. Verschuiving focusgebied Traditioneel stond bèta-amyloïde, een eiwit […] The post Nieuwe bloedtest voorspelt begin Alzheimer-symptomen appeared first on Newsmonkey.

Nieuwe bloedtest voorspelt begin Alzheimer-symptomen #Alzheimer #bloedtest #gezondheid #onderzoek #pTau217

LinkedIn This link will take you to a page that’s not on LinkedIn

ALSO IN THIS ISSUE
Unimpressive results from big #MCED trial - more data to come?
Frustration with “The certain uncertainty of an #Alzheimers diagnosis”
Can #ptau217 predict when Alzheimer's symptoms will start?
Announcing the new #OnTargetPodcast

lnkd.in/g5gsX_dT

#sensitiveandspecific#diagnostics

Bar graphs titled 'Figure 3. Economic Impact of 3 Phosphorylated Tau 217 Testing Strategies Across Biological Subgroups', 'A UGOT cohort' and 'B Roche cohort' displays 'Total cost, $1000' across subgroups like CKD, Underweight, Obesity & Anemia.

Biologically informed plasma #pTau217 thresholds improved diagnostic accuracy for amyloid PET positivity in patients with #CKD and #anemia vs a standard single cutoff, supporting cost-efficient biomarker implementation in #AlzheimerDisease screening.

bit.ly/4rBV7NI

Two bar graphs compare the economic impact of three phosphorylated Tau 217 testing strategies across biological subgroups. Graph A shows 'UGOT cohort,' and Graph B shows 'Roche cohort,' with total costs in $1000 for subgroups: CKD, Underweight, Obesity, and Anemia.

Biologically informed plasma #pTau217 thresholds improved diagnostic accuracy for amyloid PET positivity in patients with #CKD and #anemia vs a standard single cutoff, supporting cost-efficient biomarker implementation in #AlzheimerDisease screening.

ja.ma/3NRxceU

Could Alzheimer's be predicted with a finger-prick test? An international trial has started to see if a simple finger-prick blood test could predict Alzheimer's before symptoms start.

#Alzheimers #Alzheimersdiagnostics #Alzheimersdisease #cognitivedecline #BioHermes002study #bloodbasedbiomarkertesting #bloodbasedbiomarkers #biomarkers #pTau217 #GFAP #NfL #LifeArc #GAP #UKDRI #vasculardementia #frontotemporaldementia #dementiawithLewybodies #AlzheimersAssociation
zurl.co/64c0o

2️⃣ #Ikerketa honek jauzi metodologiko garrantzitsua egiten du:
🧪 odol-biomarkatzaileak erabiliz (plasma #pTau217), Alzheimerreko patologia garunean dagoen ala ez estimatzeko.

Landmark Study Utilizes ALZpath Blood Test for Early Alzheimer's Detection A groundbreaking study using ALZpath's blood test identifies early signs of Alzheimer's in older adults, marking significant advancements in early detection strategies.

Landmark Study Utilizes ALZpath Blood Test for Early Alzheimer's Detection #USA #Alzheimer's_Disease #Carlsbad,_California #ALZpath #pTau217

ALZpath and Siemens Healthineers Partner to Enhance Alzheimer's Diagnostics via Blood Tests ALZpath, Inc. has signed a licensing agreement with Siemens Healthineers to enhance global accessibility to blood-based Alzheimer's disease diagnostics through advanced testing technology.

ALZpath and Siemens Healthineers Partner to Enhance Alzheimer's Diagnostics via Blood Tests #USA #Siemens_Healthineers #Carlsbad #ALZpath #pTau217

Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions.

🔗See the full list of posters & presentations: alzpath.bio/wp-content/u...

How reliable are blood-based pTau217 tests compared to PET or CSF?

Studies show blood tests powered by the ALZpath #pTau217 antibody perform comparably to CSF testsfor detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.

🔗Learn more: alzpath.bio/faqs

ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for 'Diagnostics Innovation of the Year' | ALZpath Transformative Antibody Recognized for Advancing Global Alzheimer's Disease Detection

ALZpath’s proprietary #pTau217 antibody has been named Diagnostics Innovation of the Year by the 2025 #BioTechBreakthroughAwards — recognizing its impact in advancing earlier, more accessible #AlzheimersDisease detection.

🔗Read more: alzpath.bio/alzpath-prop...

【Labcorp、アルツハイマー病向け初のFDA承認血液検査を全米展開】

✔ FDA初承認のアルツハイマー病向け血液検査（IVD）
✔ 陽性的中率92%、陰性的中率97%の高精度
✔ 全米2,200か所のLabcorpセンターで提供開始
✔ 50歳以上の認知機能低下を示す成人が対象

#Labcorp #Fujirebio #Lumipulse #Alzheimers #pTau217 #BetaAmyloid42 #FDA承認 #体外診断 #認知症 #医療DX #PrecisionMedicine

ALZpath's pTau217 Antibody Triumphs at BioTech Breakthrough Awards for Diagnostics Innovation ALZpath's pTau217 antibody has been awarded 'Diagnostics Innovation of the Year,' enhancing early Alzheimer’s detection capabilities globally.

ALZpath's pTau217 Antibody Triumphs at BioTech Breakthrough Awards for Diagnostics Innovation #USA #Carlsbad #ALZpath #pTau217 #Alzheimer

The three non-negotiable pillars of Alzheimer’s blood testing - PMLiVE Why sensitivity, access and education will define scalable Alzheimer’s diagnostics

In a new article from PM Live, ALZpath Distinguished Scientific Advisor Dr. Henrik Zetterberg shares three pillars advancing Alzheimer’s blood testing - sensitivity, accessibility, and education - powered by biomarkers like pTau217.

Read now: pmlive.com/intelligence...

#ptau217 #alzheimers

We’re headed to #CTAD2025 in San Diego!

ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.

Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.

#AlzheimersDisease #Research

Alamar Biosciences Launches Groundbreaking NULISAqpcr™ BD-pTau217 for Alzheimer's Research Alamar Biosciences has unveiled the innovative NULISAqpcr™ BD-pTau217 assay, revolutionizing non-invasive brain biomarker detection for Alzheimer's research.

Alamar Biosciences Launches Groundbreaking NULISAqpcr™ BD-pTau217 for Alzheimer's Research #USA #Fremont #Alamar_Biosciences #NULISAqpcr #pTau217

Alamar Biosciences Unveils Groundbreaking NULISAqpcr™ BD-pTau217 Test for Alzheimer's Research Alamar Biosciences introduces NULISAqpcr™ BD-pTau217, a novel blood test enabling early detection of Alzheimer's biomarkers, enhancing research accuracy and precision.

Alamar Biosciences Unveils Groundbreaking NULISAqpcr™ BD-pTau217 Test for Alzheimer's Research #USA #Fremont #Alamar_Biosciences #Alzheimer's_Research #pTau217

pTau217 could change how Alzheimer’s is diagnosed Experts agree that the earlier Alzheimer's disease is detected, the sooner action can be taken. And so, the key to preventing deterioration is identifying the most effective early biomarkers, those th...

#pTau217 could change how Alzheimer’s is diagnosed. BioWorld News explores its potential for earlier detection and treatment monitoring, with insight from ALZpath VP of R&D Lee Honigberg, PhD.

Read the full article: www.bioworld.com/articles/724...

#AlzheimersDisease #BloodBiomarkers #Diagnosis

💜 Yesterday was #WorldAlzheimersDay, honoring the millions living with Alzheimer’s disease and the families who support them.

At ALZpath, we’re committed to earlier, accessible blood-based diagnosis with #pTau217— because knowing sooner changes everything.

🔗Learn more at: www.alzpath.bio

🧠 Which plasma biomarker best detects Alzheimer’s disease?

A head-to-head study (Alzheimer’s & Dementia, Jan 2025) compared 22 biomarkers in a memory clinic. The results: #pTau217 showed the highest accuracy and strongest correlation with CSF.

📄 pmc.ncbi.nlm.nih.gov/articles/PMC...

Visual showing a test tube being held up. And an image of Jake Hunter, CBO of ALZpath. The caption "Executive Interview: Jacob Hunter".

In a new executive interview with Drug Development & Delivery, our Chief Business Officer, Jacob Hunter shares how ALZpath’s #pTau217 antibody is enabling earlier, scalable detection of #AlzheimersDisease.

🔗Learn more in the full interview: drug-dev.com/executive-in...

#Antibody #ALZpath

Expanding the Presence of the ALZpath Blood Test in Alzheimer Disease Research: Mike Banville At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WA...

At this year’s #AAIC25, ALZpath CEO Mike Banville joined NeurologyLive to discuss how the ALZpath proprietary #pTau217 antibody is powering blood-based testing to enable earlier, scalable Alzheimer’s disease detection. 🧠💜

📌Watch the full interview here: www.neurologylive.com/view/expandi...

A pivotal step for Alzheimer’s disease care: The @alzassociation.bsky.social has released its first guideline on blood-based biomarker testing.

We're proud to see growing validation of blood-based tests, including those powered by ALZpath’s #pTau217 antibody, for earlier, more accurate diagnosis.

Significant Advances in Alzheimer's Diagnostics with ALZpath's pTau217 Antibody at AAIC At the AAIC conference, ALZpath highlights breakthroughs involving its pTau217 antibody for Alzheimer's diagnostics and treatment development.

Significant Advances in Alzheimer's Diagnostics with ALZpath's pTau217 Antibody at AAIC #United_States #Alzheimer's #Carlsbad #ALZpath #pTau217

‼️ #AAIC25! Make sure to stop at Dr. Deling He's poster that looks at plasma p-Tau 217 elevation and proper name delayed recall TODAY! ‼️ #dementia #Alzheimers #tau #Neurology #Neuroscience #ADRD #ENDALZ #plasma #ptau217 #delayedrecall

At-Home Alzheimer’s Testing Is Here: Are Physicians Ready? Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, posing new challenges for physician-patient communication.

Story I did for @medscape.com looking at the burgeoning market of direct-to-consumer blood-based biomarker tests for #Alzheimers and #dementia. Anyone with money can buy these now.

#pTau217 #MedSky #PsychSky #NeuroSky #neurology #geriatrics #brain #brainhealth

ALZpath is headed to Toronto for #AAIC25!

If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect.

Email jacob@alzpath.bio to set up a meeting.

#AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath